Johnson & Johnson - 15 Year Stock Price History | JNJ
Historical daily share price chart and data for Johnson & Johnson since 2011 adjusted for splits and dividends. The latest closing stock price for Johnson & Johnson as of June 12, 2026 is 240.87.
- The all-time high Johnson & Johnson stock closing price was 247.11 on March 02, 2026.
- The Johnson & Johnson 52-week high stock price is 251.71, which is 4.5% above the current share price.
- The Johnson & Johnson 52-week low stock price is 149.04, which is 38.1% below the current share price.
- The average Johnson & Johnson stock price for the last 52 weeks is 204.57.
| Johnson & Johnson Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 230.5988 | 205.0530 | 247.1130 | 202.0460 | 240.8700 | 17.69% |
| 2025 | 165.9674 | 138.1970 | 211.7970 | 136.3160 | 204.6570 | 47.48% |
| 2024 | 146.8477 | 148.7910 | 159.3340 | 135.3760 | 138.7720 | -4.81% |
| 2023 | 146.7693 | 160.8570 | 162.7160 | 134.3490 | 145.7870 | -8.58% |
| 2022 | 153.6930 | 150.8890 | 164.6670 | 139.9950 | 159.4660 | 5.97% |
| 2021 | 143.7066 | 134.2760 | 155.9110 | 132.1520 | 150.4760 | 11.44% |
| 2020 | 123.3853 | 121.9260 | 135.0310 | 93.4254 | 135.0310 | 10.82% |
| 2019 | 111.0745 | 103.7820 | 122.3190 | 102.1330 | 121.8430 | 16.22% |
| 2018 | 106.5849 | 110.1210 | 120.1030 | 95.7467 | 104.8380 | -5.13% |
| 2017 | 101.3354 | 89.3011 | 113.0160 | 86.1558 | 110.5090 | 24.43% |
| 2016 | 86.4019 | 75.3310 | 95.3713 | 71.7849 | 88.8154 | 15.33% |
| 2015 | 73.6707 | 76.1043 | 78.9072 | 67.5236 | 77.0104 | 1.14% |
| 2014 | 72.4348 | 64.4937 | 79.0168 | 61.3693 | 76.1407 | 17.34% |
| 2013 | 59.8885 | 48.7099 | 67.7527 | 48.6412 | 64.8905 | 34.62% |
| 2012 | 45.1891 | 43.6831 | 49.4280 | 41.7287 | 48.2011 | 10.85% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |